Trial Profile
Study on Pharmacokinetics of Newly Developed ANtiretroviral Agents in HIV-infected pregNAnt Women (PANNA)
Status:
Recruiting
Phase of Trial:
Phase IV
Latest Information Update: 22 Feb 2024
Price :
$35
*
At a glance
- Drugs Abacavir (Primary) ; Abacavir/dolutegravir/lamivudine (Primary) ; Atazanavir (Primary) ; Bictegravir/emtricitabine/tenofovir alafenamide (Primary) ; Cabotegravir (Primary) ; Cobicistat (Primary) ; Cobicistat/darunavir (Primary) ; Cobicistat/elvitegravir (Primary) ; Darunavir (Primary) ; Dolutegravir (Primary) ; Doravirine (Primary) ; Doravirine/lamivudine/tenofovir disoproxil fumarate (Primary) ; Efavirenz/emtricitabine/tenofovir-disoproxil-fumarate (Primary) ; Elvitegravir (Primary) ; Emtricitabine (Primary) ; Emtricitabine/rilpivirine/tenofovir alafenamide (Primary) ; Emtricitabine/tenofovir alafenamide (Primary) ; Emtricitabine/tenofovir disoproxil fumarate (Primary) ; Enfuvirtide (Primary) ; Etravirine (Primary) ; Fosamprenavir (Primary) ; Indinavir (Primary) ; Lamivudine (Primary) ; Lamivudine/zidovudine/abacavir (Primary) ; Maraviroc (Primary) ; Raltegravir (Primary) ; Rilpivirine (Primary) ; Rilpivirine (Primary) ; Ritonavir (Primary) ; Tenofovir alafenamide (Primary) ; Tenofovir disoproxil fumarate (Primary) ; Tipranavir (Primary)
- Indications HIV infections
- Focus Pharmacokinetics
- Acronyms PANNA
- 21 Dec 2023 Cabotegravir prolonged-release IM injection (Vocabria) is added as a test drug.
- 21 Dec 2023 Planned number of patients changed from 176 to 230.
- 16 Mar 2021 Planned number of patients changed from 230 to 176.